Protective Effect of Silybin in Rats Liver Toxicity
Keywords:
silybin, hepatotoxicity, alcohol, CCl4Abstract
Silybin is a flavonoid extracted from the herb Armurariu (Silybum marianum) and has the potential efficacy in the treatment of liver disease. The aims of this study were to investigate the effect of alcohol and CCl4 on liver histology and the capacity of silybin to ameliorate the hepatotoxicity. Thirty adult male Wistar rats were used in the study. Liver toxicity was induced by dietary alcohol administration and CCl4 intra-peritoneal injection. The protective effect of silibin was investigated by co-administration of silybin with these toxic agents. Hepatocellular and extracellular matrix integrity was determined by histopathological and immunohistochemical study. Hematoxylin-Eosin and trichrome stains sections were studied in each case. For immunohistochemistry we used monoclonal anti-collagen IV primary antibody. Light microscopic evaluation of liver tissues shows that control and silibin treated groups has normal liver structure. In the toxicity groups, HE and trichromic staining showed hepatocellular necrosis, inflammatory infiltrate and proliferating collagen fibers. Immunoexpression of collagen IV was variable. In the control group, we found negative expression. Collagen IV displays positive immunoreaction in hepatotoxicity groups, at the level of the areas rich in inflammatory infiltrate and with degenerative aspect. After this study, we can conclude that silybin, in rats, has protective effects.
References
Wu Jhy-Wen, Lin Lie-Chwen, Hung Shih-Chieh, Lin Chi-Hung, Chi Chin-Wen, Tsai Tung-Hu. Hepatobiliary Excretion of Silibinin in Normal and Liver Cirrhotic Rats. Drug metabolism and disposition. 2008, 36: 589–596.
Katiyar S.K. Silymarin and skin cancer prevention: Antiinflammatory, antioxidant and immunomodulatory effects. Int J Oncol 2005, 26: 169–176.
Katiyar S.K, Roy A.M, Baliga M.S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-Bax,cytochrome c release, and caspase activation. Mol Cancer Ther 2005; 4(2):207–216.
Gažák R., Svobodová A., Psotová J., Sedmera P., Přikrylová V., Walterová D., Křen V. Oxidised derivatives of silybin andtheir antiradical and antioxidant activity. Bioorg Med Chem, 2004, 12:5677–5687.
Pelt J.V., Verslype C., Crabbé T., Zaman Z., Fevery J. Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol & Alcoholism 2003, 38(5): 411–414.
Křen V., Walterováb D. Silybin and silymarin – new effects and applications. Biomed. Papers 2005, 149(1): 29–41.
Singh R.P., Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 2005; 41: 1969–79.
Jeong D.H., Lee G.P, Jeong W.I., Do S.H., Yang H.J., Yuan D.W., Park H.Y., Kim K.J., Jeong K.S. Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis. World J Gastroenterol 2005; 11(8): 1141-1148.
Li J., Niu J.Z., Wang J.F., Li Y., Tao X.H. Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fi brosis rat model. World J Gastroenterol 2005;11(41):6483-6488.
Lv X.H., Liu D.P., Wang Y., Wang B.Y., Fu B.Y., Liu C.R. Traditional Chinese medicine Kang Xian Fu Fang is effective for prophylaxis and treatment of alcoholic liver disease in rats. Hepatobiliary Pancreat Dis Int 2007; 6: 182-187.
Gujrati V., Patel N., Rao V.N., Nandakumar K., Gouda T.S., Shalam M., Santa Kumar S.M. Hepatoprotectivi activity of alcoholic and aqueous extract of leaves of Tylophora indica in rats. Indian J Pharmacol, 2007, 39(1), 43-47.
Saravanan N., Nalini N. Hemidesmus indicus protects against ethanol-induced liver toxicity. Cellular & molecular biology letters 2008, 13: 20-37.
Zhang Li-Juan, Chen Yun-Xin, Chen Zhi-Xin, Huang Yue-Hong, Yu Jie-Ping, Wang Xiao-Zhong: Effect of interleukin-10 and platelet-derived growth factor on expressions of matrix metalloproteinases-2 and tissue inhibitor of metalloproteinases-1 in rat fibrotic liver and cultured hepatic stellate cells World J Gastroenterol 2004;10(17): 2574-2579.
Qing-He Nie, Guo-Rong Duan, Xin-Dong Luo, Yu-Mei Xie, Hong Luo, Yong-Xing Zhou. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 2004;10(1):86-90.
Onori P., Morini S., Franchitto A., Sferra R., Alvaro D., Gaudio E. Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats. J Hepatol 2000; 33:555-563.
Kharpate S., Vadnerkar G., Jain D., Jain S.. Evaluation of hepatoprotective activity of ethanol extract of Ptrospermum acerifolium ster leaves. Indian J Pharm. Sci. 2007, 69(6), 850-852.
Eminzade S., Uraz F., Izzettin F.V. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutrition & Metabolism 2008, 5(18): 1-7.
Tasduq S.A., Peerzada K., Koul S., Bhat R., Johri R.K. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res 2005, 31:132-135.
Pal R., Vaiphei K., Sikander A., Singh K., Rana S.V. Effect of garlic on isoniazid and rifampicin-induced hepatic injury in rats. World Gastroenterol 2006, 12:636-639.
Santhosh S., Sini T.K., Anandan R., Mathew P.T. Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats. Toxicology 2006, 219:53-59.
Ahmed, B., Khan, S. A., Alam T. Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1, 4-dioxane ring system. Pharmazie 2003, 58: 173- 176.
Lee T.Y., Mai L.M., Wang G.J., Chiu J.H., Lin Y.L., Lin H.C. Protective mechanism of salvia miltiorrhiza on carbon tetrachloride-induced acute hepatotoxicity in rats. J. Pharmacol. Science 2003, 91:202-210.
Madani H., Talebolhosseini M., Asgary S., Naderi G.H. Hepatoprotective Activity of Silybum marianum and Cichorium intybus Against Thioacetamide in Rat. Pakistan Journal of Nutrition 2008, 7(1): 172-176.
Kang J.S., Jeon Y.J., Park S.K., Yang K.H., Kim H.M. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1 beta and prostaglandin E2 synthesis by silymarin. Biochem. Pharmacol. 2004, 67: 175-181.
Wellington K., Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001, 15: 465 – 89.
Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006, 124: 491-504.
Gu M., Dhanalakshmi S., Singh R.P., Agarwal C., Agarwal R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res 2004; 64:6349–56.
Nomura M., Takahashi T., Nagata N., Tsutsumi K., Kobayashi J., Akiba T., Yokogawa K., Moritani S,. Miyamoto K.I. Inhibitory Mechanisms of Flavonoids on Insulin-Stimulated Glucose Uptake in MC3T3-G2/PA6 Adipose Cells. Inhibitory Mechanisms of Flavonoids on Insulin-Stimulated Glucose Uptake in MC3T3-G2/PA6 Adipose Cells. Biol. Pharm. Bull. 2008, 31(7): 1403—1409
Tyagi A., Raina K., Singh RP., Gu M., Agaewal C., Harrison G., Glode M., Agarwall R. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine–induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007; 6(12):3248–55.
Singh R.P., Tyagi A., Sharma G., Mohan S., Agarwal R. Oral Silibinin Inhibits In vivo Human Bladder Tumor Xenograft Growth Involving Down-Regulation of Survivin. Clin Cancer Res 2008;14(1) 300-308.
